A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Trial Details

NCT ID
NCT07281001
Phase
NA
Sponsor
Blokhin's Russian Cancer Research Center
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Patients aged over 18 years old.
  • Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
  • Patients has received Trastuzumab Deruxtecan
  • Available medical history.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →